Last updated: 2026-09-16 09:46:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
EyePoint, Inc. (EYPT) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NASDAQ. The stock is currently priced at $3,74, with a market capitalisation of $366,40M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,64 to $19,11. This page covers its latest market performance, valuation, price trends and company information.
$366,40M | |
$3,69 | |
$39,40 | |
$2,19 | |
$3,66 | |
1,01K | |
3,49M | |
-- | |
$19,11 | |
$3,64 | |
-- | |
-- |
EyePoint, Inc. (EYPT) is trading at $3,74 in pre-market trading as of 2026-09-16 09:44:00, up 2,05% ($0,07) from the previous close of $3,66
Pre-market trading shows how investors are pricing EYPT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, EyePoint, Inc. (EYPT) moved from $4,58 to $3,74, representing a decline of 18,45% ($0,85).
The stock traded between $3,64 and $4,69 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2,95 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,6%
EYPT is currently trading at $3,74, placing it 0,6% of the way from its 52-week low of $3,64 to its 52-week high of $19,11. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 214 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of EyePoint, Inc. (EYPT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.